What death spiral?
Premium increase unlikely in 2015.
With all the technological setbacks and glitches of healthcare.gov at the end of 2013, and the clock ticking on open enrollment, concerns about low enrollment of the young and healthy have been abundant.
However, a recent study by the Kaiser Family Foundation (KFF) downplayed concerns that low enrollment of young adults might lead to a "death spiral.”
The study stated that under a worst-case scenario in which only 25% of enrollees are age 18 to 34, insurers would have to raise premiums by 2.5% in 2015. Similarly, if young adults represent 33% of enrollees, premiums would be raised by 1.1%.
With the addition of ACA transitional policies that allow insurers to keep premiums low as the risk pool settles in first three years, it's unlikely that premiums will increase in 2015.
In this episode of the "Meet the Board" podcast series, Briana Contreras, Managed Healthcare Executive editor, speaks with Ateev Mehrotra, a member of the MHE editorial advisory board and a professor of healthcare policy and medicine at Harvard Medical School. Mehtrotra is also a hospitalist at the Beth Israel Deaconess Medical Center in Boston. In the discussion, Contreras gets to know Mehrotra more on a personal level and picks his brain on some of his research interests including telehealth, alternative payment models and price transparency.
Listen
Updated: FDA Committee, Concerned about Bias, Votes No on Psychedelic in PTSD
June 5th 2024Patients with PTSD in the clinical trials of midomafetamine were able to guess whether they received treatment or placebo. Regulators and advisory committee members said this could have impacted efficacy results. FDA’s decision is expected by Aug. 11, 2024.
Read More
Eric Levin talks PBMs and how Scripta is Tackling the Market's Challenges for Patients
July 22nd 2020MHE's Briana Contreras spoke with CEO of Scripta, Eric Levin. The two discussed the current state of the pharmacy benefit market and how the Scripta organization has been assisting its clients and their prescriptions prior to the COVID-19 pandemic and during.
Listen
